Combination of aprepitant, palonosetron and dexamethasone as antiemetic prophylaxis in lung cancer patients receiving multiple cycles of cisplatin-based chemotherapy

International Journal of Clinical Practice

Volumn 66, Issue 8, 2012, Pages 753-757

  Longo, F ^a   Mansueto, G ^b   Lapadula, V ^a   Stumbo, L ^a   Del Bene, G ^a   Adua, D ^a   De Filippis, L ^a   Bonizzoni, E ^c   Quadrini, S ^a  

^a POLICLINICO UMBERTO I   (Italy)

^b F Spaziani Hospital   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

APREPITANT; CISPLATIN; DEXAMETHASONE; PALONOSETRON;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONSTIPATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROPHYLAXIS; TREATMENT RESPONSE;

EID: 84863982498     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2012.02969.x     Document Type: Article

References (25)

1. Jemal A, Siegel R, Ward E, et al., Cancer Statistic, 2009. CA Cancer J Clin 2009; 59: 225-49.
2. Dong X, Huang J, Cao R, et al., Palonosetron for prevention of acute and delayed nausea and vomiting in non-small-cell lung carcinoma patients. Med Oncol 2010; 28 (4): 1425-9.
3. Feinberg B, Gilmore J, Haislip S, et al., Impact of initiating antiemetic prophylaxis with palonosetron versus ondansetron on risk of uncontrolled chemotherapy-induced nausea and vomiting in patients with lung cancer receiving multi-day chemotherapy. Sup Care Cancer 2012; 20: 615-23.
4. Roila F, Herrstedt J, Aapro M, et al., Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 2010; 21 (Suppl 5): v232-43.
5. Basch E, Prestrud AA, Hesketh PJ, et al., Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2011; 29 (31): 4189-98.
6. Hesketh PJ,. Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist 1999; 4: 191-6. (Pubitemid 29297482)
7. Rubenstein EB,. Costs and benefits of outpatient therapy. Sup Care Cancer 1994; 2 (5): 307-11.
8. Eisenberg P, Figuero-Vadillo J, Zamora R, et al., 99-04 Palonosetron Study Group. Improved prevention of moderately emetogenic chemotherapy induced nausea and vomiting with palonosetron, a pharmacologically novel 5HT3 receptor antagonist. Results of a phase III, single dose trial versus dolasetron. Cancer 2003; 98 (11): 2473-82. (Pubitemid 37466663)
9. Gralla R, Lichinitser M, Van Der Vegt S, et al., Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003; 14: 1570-7. (Pubitemid 37304615)
10. Aapro MS, Grunberg SM, Manikhas GM, et al., A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006; 17 (9): 1441-9. (Pubitemid 44400384)
11. Rubenstein EB, Gralla RJ, Eisenberg P, et al., Palonosetron (PALO) compared with ondansetron (OND) or dolasetron (DOL) for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV). Combined results of two Phase III trials. Proc Am Soc Clin Oncol 2003; 22: 729.
12. Saito M, Aogi K, Sekine I, et al., Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 2009; 10 (2): 115-24.
13. Hesketh PJ, Grunberg SM, Gralla RJ, et al., The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomised, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin: the aprepitant protocol 052 study group. J Clin Oncol 2003; 21 (22): 4112-9. (Pubitemid 46606178)
14. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al., Addition of the neurokinin 1 receptor anatagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting: results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003; 97 (12): 3090-8. (Pubitemid 36676265)
15. Schmoll HJ, Aapro MS, Poli-Bigelli S, et al., Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 2006; 17 (6): 1000-6. (Pubitemid 43778994)
16. Italian Group for Antiemetic Research. Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. J Clin Oncol 1998; 16: 2937-42.
17. Grunberg SM,. Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis. Ann Oncol 2007; 18: 233-40. (Pubitemid 46323087)
18. Grunberg S, Clark-Snow RA, Koeller J,. Chemotherapy-induced nausea and vomiting: contemporary approaches to optimal management: Proceedings from a symposium at the 2008 Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting. Sup Care Cancer 2010; 18 (Suppl 1): 1-10. PMID 20084406
19. Schwartzberg L, Jackson J, Jain G, et al., Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting. Expert Rev Pharmacoecon Outcomes Res 2011; 11 (4): 481-8.
20. De Wit R, Van Den Berg H, Burghouts J, et al., Initial high anti-emetic efficacy of granisetron with dexamethasone is not maintained over repeated cycles. Br J Cancer 1998; 77 (9): 1487-91. (Pubitemid 28190750)
21. De Wit R, Herrstedt J, Rapoport B, et al., Addition of the oral NK 1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol 2003; 21: 4105-11. (Pubitemid 46606177)
22. Longo F, Mansueto G, Lapadula V, et al., Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy. Sup Care Cancer 2011; 19 (8): 1159-64.
23. Hesketh PJ, Kris MG, Grunberg SM, et al., Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997; 15: 103-9. (Pubitemid 27020563)
24. Lindley C, McCune JS, Thomason TE, et al., Perception of chemotherapy side effects cancer versus non cancer patients. Cancer Pract 1999; 7: 59-65. (Pubitemid 29148608)
25. Basch E,. The Missing Voice of Patients in Drug-Safety Reporting. N Engl J Med 2010; 362: 10.